Background: Severe alcoholic hepatitis patients have high mortality and limited
the latter two predicting steroid nonresponse in 94% patients at baseline in peripheral plasma. Microvesicle levels correlated with histological and liver disease severity indices. Whereas, in non-responders hepatic vein CD34+ cells were lower (P = 0.02), the CD34+ microvesicles there from were higher (P = 0.04), thus suggesting impaired regeneration. Also, microvesicles of 0.2-0.4 lm size were higher in nonresponders (P < 0.03) at baseline. Microvesicles from patients trigger more (P = 0.04) ROS generation, TNF-a production (P = 0.04) and up-regulate pro-inflammatory cytokine related genes in neutrophils in vitro.
Conclusions: Pre-therapy peripheral plasma levels of CD34 + and ASGPR + microvesicles are reliable non-invasive markers of steroid nonresponse and mortality in patients with severe alcoholic hepatitis.
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| INTRODUCTION
Alcoholic liver disease is one of the most common forms of liver disease and the spectrum is from simple steatosis to alcoholic steatohepatitis to severe alcoholic hepatitis (SAH) with high mortality and limited treatment options. [1] [2] [3] The early detection of high-risk patients, prompt intervention, and accurate prognostic stratification is pivotal. [4] [5] [6] [7] However, the time necessary to prognosticate a therapeutic strategy and response is crucial to avoid damage from intervening too early or too late and to guide therapy in patient s at high risks of short-term mortality. Till date, prednisolone is the most effective and recommended treatment for patients with SAH, being the only treatment demonstrating modest improvement in survival at 28 days. 8, 9 Early improvement in liver function with corticosteroid therapy is associated with decrease in short-term mortality. Using the Lille Model can assess this improvement but the Lille score on day 7 ≥ 0.45 indicates non-response. 10 Almost 40% of patients with SAH are classified as nonresponders to corticosteroids, which is associated with a 6-month survival as low as 25% and dictates discontinuation of prednisolone owing to lack of therapeutic benefit. 11 However, this means that assessment requires at least 7 days of high-dose corticosteroids, and nonresponse to corticosteroids is highly predictive of sepsis. 12 Thus, there is a need for improved non-invasive tools, which can reliably predict response before initiation of steroid therapy.
Upon stress, activation or early apoptosis in cells releases membrane-bound extracellular vesicles such as microvesicles (MVs) (0.1-1 lm). 13 We aimed to identify association of MVs with severe acholic hepatitis non-response, which may pave way for non-invasive tools for predicting non-response to steroid therapy even at the baseline. The MVs are known to serve as putative indicators of disease conditions. 14,15 A number of studies point out that MVs can affect several cellular functions. [16] [17] [18] Notably, released MVs do not only stay in the tissue of origin, but also circulate in the blood. 19 Hepatic venous blood represents the liver microenvironment and a snapshot of MVs can give us an insight of intra-hepatic cellular injury.
In this study, we provide a proof of concept that by identifying the cellular origin, quantity and the size of circulatory MVs, one can identify at baseline the SAH patients who are unlikely to respond to steroid therapy. Investigation of MVs in the hepatic venous blood allowed us to understand whether these MVs reach the peripheral blood. We also investigated the role of MVs in activating immune cells and inducing inflammatory signals in SAH patients. Blood samples were taken from healthy or patients who gave informed consent. Along with the peripheral blood plasma, the hepatic venous blood was collected during trans-jugular liver biopsy procedure, before taking the biopsy to study microvesicles.
| PATIENTS AND METHODS

| Patients
| Histopathology
The liver biopsies were assessed blindly by an experienced hep- 
| Isolation of circulating microvesicles by differential ultracentrifugation
Circulating MVs were isolated from platelet free plasma using differential ultracentrifugation. The collected pellet was then enumerated using flow cytometer to confirm microvesicles population. Detailed protocol of sample collection, processing and isolation were followed according to the special guidelines by ISTH for extracellular vesicles to avoid any artifacts (Data S1).
| Characterisation of circulating microvesicles using multicolor flow cytometer
Microvesicles by flow cytometer, spherotech latex beads (IL, USA),
were used a mixture of microbeads of different sizes (0.22 lm, 0.44 lm, 0.88 lm, and 1.0 lm). The absolute count of microvesicles was done using TruCount beads at 10 000 events (Data S1). ) MVs from severe alcoholic hepatitis patients and healthy subjects for studying oxidative burst in neutrophils and TNF-a production in both monocytes and neutrophils. The mRNA levels of various candidate genes related to inflammatory signalling pathways were studied using real time qPCR (Data S1).
| Statistical analysis
The baseline clinical parameters were calculated as median and range (min-max). The univariate statistical techniques applied were Student's t test/Mann-Whitney U-test and one-way analysis of variance or Kruskal-Wallis test, wherever necessary. Spearman's-correlation was calculated for correlation analysis. All statistical tests were 2-tailed, and a significance level was set at P < 0.05. Statistical analyses were performed using SPSS for Windows version 20 (IBM Analytics, USA). The multivariate projection analysis was also per-
formed using the open source software http://www.metaboan alyst.ca. The parameters in which the P values were significant were further considered for multivariate analysis. Also, the P values were normalised using Bonferonni correction.
3 | RESULTS
| Patient characteristics
Based on Lille score of <0.45 calculated after day 7 of steroid therapy, patients were classified as responders (R, n = 71) and nonresponders (NR, n = 30). The baseline parameters of both responders and nonresponders were similar in the two groups ( Table 1 ). The platelet and white cell counts were significantly (P < 0.05) lower in responders at baseline. Severity scores like Child-Pugh Score, Model for end stage liver disease (MELD), and Maddrey's discriminant function (DF) were not significantly different between the groups; though the mortality was higher in nonresponders. (Table 1 ).
| Circulating microvesicles profile in SAH patients and association with corticosteroid response
We investigated the MV profile in responders(R) and nonresponders origin and we found significant increase in nonresponders than responders (P = 0.002, q* = 0.02) ( Figure 1A ). Also, post-therapy, at day 7, the MV levels associated with HSCs and hepatocytes remained higher (P < 0.001 and P < 0.04, respectively) ( Figure S1A) in nonresponders than responders, whereas other MV levels were found unchanged.
| Diagnostic performance of microvesicles for prediction of non-response
To confirm the findings of univariate analysis, multivariate analysis was done. The clustering observed using the Principal component analysis (PCA) for various comparisons was improved further for identification of discriminating variables by employing the PLSDA model. It was observed that the microvesicles from peripheral blood could segregate nonresponders from responders ( Figure S1B ). PCA and the PLS-DA plot was significant with R 2 = 0.55, Accuracy 0.89 and q 2 = 0.45. Furthermore, the parameters, in which the P values were < 0.05 were considered for multivariate analysis. These MVs also correlated with the MELD and CTP scores (Table S1 ).
Furthermore, the area under ROC curve (AUROC) analysis showed that MV signatures, specifically CD34+ and ASGPR+ associ- (Table S2 ).
| Differential Microvesicle levels predict mortality in SAH patients
To identify predictors for 1-month mortality, we investigated baseline demographic and biochemical parameters, liver severity indices and survival. Ten percent of patients died by 1 month and 30% by 3-months. There was a significant correlation among all the MV levels. Of these, CD34+ and ASGPR+ MVs at day 0 were considered for multivariate analysis for mortality owing to the fact that the area under the curve was maximum for CD34+ and ASGPR+ MVs. Multivariate analysis, using cox regression forward step-wise selection method, identified the presence of CD34+ and ASGPR+ MVs could significantly predict the mortality in less than 7 days. AUROC clearly showed that CD34+ and ASGPR+ MVs could predict survival in both responders and nonresponders. The MVs related to CD34+ and ASGPR+ differentiated non-survivors from survivors at 1 month significantly ( Figure 1C ). 3.7 | Increased CD34+ Microvesicle levels in hepatic vein plasma in Non-responderss
We also compared MVs in hepatic venous blood, which closely reflects the microenvironment of the liver. The hepatic vein plasma, the CD34+ MV levels were significantly higher in NRs than R. Also, in hepatic vein plasma carried significantly higher levels of CD34+MVs in NR than R as compared to the peripheral blood Figure 2A ). Other MVs along with their respective cell numbers were comparable between the peripheral blood and the hepatic vein blood (Figure 2A ). Although upon studying the percentages of CD34+ cells, this is quite in contrast to the CD34+ MVs and we found cell number lower in the hepatic vein blood ( Figure 2B ). Furthermore, we also found that the protein expression of CD34+ cells in liver biopsies of nonresponders (n = 10) than responders (n = 10)
were also significantly low (P = 0.03). Although, ASGPR was found higher in nonresponders ( Figure S2 ). MVs) were isolated and co-cultured with healthy neutrophils and monocytes (1 x 10 5 cells) in vitro (n = 4). The ROS production from neutrophils using dihydrohodamine-123 by FACS and we found, compared to healthy controls, from SAH (P < 0.04) patients, showed significant increase in ROS production (68.4% vs 89.2%). (Figure 3A) .
Also, the intracellular TNF-a production in neutrophils was also increased with MVs from SAH (3% vs 0.1%, P < 0.04) patients. But, no significant changes were found in monocytes after stimulation with MVs from diseased or healthy subjects ( Figure 3B) . on the other hand, were down regulated ( Figure 3C ). In monocytes, only the genes associated with pro-inflammatory cytokines(ILs) and sterile inflammation such as (NLRP3, Casp1) were up regulated whereas all the other genes were down regulated after stimulation with MVs from SAH patients ( Figure 3C ). The sterile inflammation genes were up regulated in monocytes. The NLRP3 expression was also studied using immunofluorescence in monocytes after co-culture with MVs from SAH patients and controls. We found significantly higher expression of NLRP3 after SAH and control MVs than no treatment (1.02 AE 0.1 vs 4.14; 3.23 AE 1.2 respectively) but no significant difference was found in SAH vs. HC ( Figure S4 ).
| DISCUSSION
The The best treatment option so far available for SAH patients is corticosteroids, though the short-term survival at 28 days is only around 50%-60%. 1 It has been reported that in alcoholic liver cirrhosis, the clinical features are difficult to predict mortality. 20 Lille score ≥ 0.45 has been proposed as an indicator of corticosteroid response. However, the drawback of this approach is that the nonresponsiveness can be assessed only at day 7 of the therapy. 21 In addition, steroids possibly cause suppression of hepatic regeneration and repair. 22 Thus, it is important to identify patients unlikely to respond to corticosteroid therapy prior to start of steroids. This study identifies that microvesicle levels can predict disease severity and differentiate nonresponders to steroids before the start of the therapy. We identified higher levels of MVs from various cells of origin in NRs and specifically CD34+ and ASGPR+ MVs can be utilised with 94% predictability for non-responsiveness of steroid therapy and CD34+ cells also could predict 1-month mortality in nonresponders. We know that microvesicles exist in broad range of sizes between (0.5-1 um). We observed that size of microvesicles are different among responders and nonresponders. The mechanisms behind differences in MV sizes needs to be explored and it may pave the path to assess the degree and nature of cellular injury. In fact, microvesicles are involved in cell-to-cell communication and the size might be associated with different protein interactions with
MVs to regulate the various cellular functions. We have recently reported that with increasing severity of liver cirrhosis, the derangement of haematopoietic niche and loss of HSCs increases, contributing to the haematological and immunological dysfunctions and reduced potential for regeneration. 23 The MV signatures in SAH patients validate our earlier results.). In multi-variate analysis, alcoholic hepatitis at the first biopsy was the only predictive factor of its recurrence. 24 Our liver histology data suggest that in liver of nonresponders, CD34+ cells were significantly lower than in responders.
Upon analysing the bone marrow of nonresponders and responders, we also found that CD34+ cells are lower in nonresponders (data not shown). Early apoptosis of CD34 + cells may lead to generation of higher number of CD34 + MVs, which could predict early nonresponse and mortality to corticosteroid therapy.
An additional novelty of our study is the analysis of MVs from hepatic venous blood. MV signatures from hepatic vein truly reflect F I G U R E 3 Circulating MVs trigger Inflammation, Oxidative Stress and Apoptosis in immune cells. (A), The dot blot shows the gating strategy of neutrophils population. The histograms shows the fluorescence intensity of rodamine at FL-1. (B), The dot plot shows intracellular TNF-a production with and without treatment with SAH in neutrophils and monocytes. (C), mRNA levels of the genes associated with inflammation, oxidative stress, leucocyte adhesion, antioxidants, apoptosis and sterile inflammation in neutrophils and monocytes after treatment with diseased and healthy MVs. The first bar graph shows the significant genes differentially regulated in neutrophils and the second bar shows regulated genes in monocytes the microenvironment in the liver. The results from peripheral blood was validated even in hepatic venous blood and CD34+ MVs were found higher in NRs, whereas the CD34+ cell population was found relatively lower in nonresponders than responders, suggesting the MVs might be the result of early apoptosis in HSCs in liver and MVs migrate in systemic circulation. Also, the study was carefully performed and special attention was given to avoid pre-analytical steps for the measurement of microvesicles as to avoid the artifacts in generation of particles from cells due to sample collection, preparation, processing and enumeration. A wide variety of different methods are used to measure, quantify, and phenotype microvesicles from blood samples. The nanoparticle tracking is widely used method but was not easily accessible; we used flow cytometer, which is also widely used to detect microvesicles from plasma. 25 Corticosteroids act as inhibitors of inflammatory reactions and immune mediated hepatic damage. Recent data have demonstrated a complex association between ethanol metabolism, inflammation and innate immunity in the development and progression of SAH. 26 Study from our group has already demonstrated that neutrophils act as primary inflammatory agents through production of proinflammatory mediators, release of reactive oxygen species and various cytokines. 27, 28 We assessed the potential contribution of MVs to trigger the inflammatory functions in immune cells and regulation of genes associated with inflammatory pathways. We found MVs so released have the potential to activate neutrophils, increase ROS production, TNF-a generation and trigger genes related to oxidative stress, apoptosis and pro-inflammatory cytokines. Although in monocytes they failed to show the similar effect as of neutrophils but MVs were able to stimulate sterile inflammation related genes and also NLRP3 activation ( Figure S5 ). This suggests that neutrophils activated by MVs, may be key players in immune mediated liver damage and responsible for high mortality in SAH.
In conclusion, our results document that MVs originating from hepatocytes and CD34+ haematopoietic cells can predict non-response to steroid therapy at baseline. The source of these MVs was also validated with higher levels in hepatic vein plasma of nonresponders. The haematopoietic stem cells from bone marrow may migrate to liver, but probably, a fair proportion are unable to induce effective regeneration to an unfavourable milieu and, hence possibly perish as assessed by high MV levels. MVs trigger inflammation, oxidative stress and apoptosis in immune cells, which may be responsible for non-response, and increased mortality in nonresponders.
